Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma

References

• To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204.
   PubMed Web of Science ®Google Scholar
• Hermosa JL, Sanchez CB, Rubio MC, et al. Factors associated with the control of severe asthma. J Asthma. 2010;47:124–130.
   PubMed Web of Science ®Google Scholar
• Kerkhof M, Tran TN, Soriano JB, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. 2018;73:116–124.
   PubMed Web of Science ®Google Scholar
• Marone G, Galdiero MR, Pecoraro A, et al. Prostaglandin D2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives. Expert Opin Investig Drugs. 2019;28:73–84.
   PubMed Web of Science ®Google Scholar
• Fahy JV. Type 2 inflammation in asthma–present in most, absent in many. Nat Rev Immunol. 2015;15:57–65.
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18:716–725.
   PubMed Web of Science ®Google Scholar
• Terl M, Sedlak V, Cap P, et al. Asthma management: a new phenotype-based approach using presence of eosinophilia and allergy. Allergy. 2017;72:1279–1287.
   PubMed Web of Science ®Google Scholar
• Hinks TS, Brown T, Lau LC, et al. Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1. J Allergy Clin Immunol. 2016;138:61–75.
   PubMed Web of Science ®Google Scholar
• Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47:161–175.
   PubMed Web of Science ®Google Scholar
• Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13:425–437.
   PubMed Web of Science ®Google Scholar
• Tajiri T, Matsumoto H, Gon Y, et al. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma. Allergy. 2016;71:1472–1479.
   PubMed Web of Science ®Google Scholar
• Detoraki A, Di Capua L, Varricchi G, et al. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. J Asthma. 2016;53:201–206.
   PubMed Web of Science ®Google Scholar
• Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143:1742–1751 e7.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Senna G, Loffredo S, et al. Reslizumab and eosinophilic asthma: one step closer to precision medicine? Front Immunol. 2017;8:242.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018;52: pii: 1800936.
   Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486–2496.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475–2485.
   PubMed Web of Science ®Google Scholar
• Samitas K, Zervas E, Gaga M. T2-low asthma: current approach to diagnosis and therapy. Curr Opin Pulm Med. 2017;23:48–55.
   PubMed Web of Science ®Google Scholar
• Ricciardolo FLM, Sorbello V, Folino A, et al. Identification of IL-17F/frequent exacerbator endotype in asthma. J Allergy Clin Immunol. 2017;140:395–406.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. [ Updated 2019; cited 2019 Jul 20]. Available from: www.gina.asthma.org/
   Google Scholar
• Murphy KR, Meltzer EO, Blaiss MS, et al. Asthma management and control in the United States: results of the 2009 asthma insight and management survey. Allergy Asthma Proc. 2012;33:54–64.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Bagnasco D, Ferrando M, et al. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther Adv Respir Dis. 2017;11:40–45.
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Ferrando M, Varricchi G, et al. Anti-interleukin 5 (IL-5) and IL-5Ra biological drugs: efficacy, safety, and future perspectives in severe eosinophilic asthma. Front Med (Lausanne). 2017;4:135.
   PubMed Web of Science ®Google Scholar
• Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from prospero, a prospective real-world study. J Allergy Clin Immunol Pract. 2019;7:156–164 e1.
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364:1005–1015.
   PubMed Web of Science ®Google Scholar
• Milgrom H, Fick RB Jr., Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 study group. N Engl J Med. 1999;341:1966–1973.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Galdiero MR, Loffredo S, et al. Eosinophils: the unsung heroes in cancer? Oncoimmunology. 2018;7:e1393134.
   PubMed Web of Science ®Google Scholar
• Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125:1344–1353 e2.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448–2458.
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7:46–59.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Pecoraro A, Marone G, et al. Thymic stromal lymphopoietin isoforms, inflammatory disorders, and cancer. Front Immunol. 2018;9:1595.
   PubMed Web of Science ®Google Scholar
• Friend SL, Hosier S, Nelson A, et al. A thymic stromal cell line supports in vitro development of surface IgM+ B cells and produces a novel growth factor affecting B and T lineage cells. Exp Hematol. 1994;22:321–328.
   PubMed Web of Science ®Google Scholar
• Sims JE, Williams DE, Morrissey PJ, et al. Molecular cloning and biological characterization of a novel murine lymphoid growth factor. J Exp Med. 2000;192:671–680.
   PubMed Web of Science ®Google Scholar
• Afferni C, Buccione C, Andreone S, et al. The pleiotropic immunomodulatory functions of il-33 and its implications in tumor immunity. Front Immunol. 2018;9:2601.
   PubMed Web of Science ®Google Scholar
• Gon Y, Hashimoto S. Role of airway epithelial barrier dysfunction in pathogenesis of asthma. Allergol Int. 2018;67:12–17.
   PubMed Web of Science ®Google Scholar
• Park LS, Martin U, Garka K, et al. Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: formation of a functional heteromeric complex requires interleukin 7 receptor. J Exp Med. 2000;192:659–670.
   PubMed Web of Science ®Google Scholar
• Pandey A, Ozaki K, Baumann H, et al. Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. Nat Immunol. 2000;1:59–64.
   PubMed Web of Science ®Google Scholar
• Verstraete K, Peelman F, Braun H, et al. Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma. Nat Commun. 2017;8:14937.
   PubMed Web of Science ®Google Scholar
• Biancheri P, Di Sabatino A, Rescigno M, et al. Abnormal thymic stromal lymphopoietin expression in the duodenal mucosa of patients with coeliac disease. Gut. 2016;65:1670–1680.
   PubMed Web of Science ®Google Scholar
• Calven J, Yudina Y, Hallgren O, et al. Viral stimuli trigger exaggerated thymic stromal lymphopoietin expression by chronic obstructive pulmonary disease epithelium: role of endosomal TLR3 and cytosolic RIG-I-like helicases. J Innate Immun. 2012;4:86–99.
   PubMed Web of Science ®Google Scholar
• Collison AM, Sokulsky LA, Sherrill JD, et al. TNF-related apoptosis-inducing ligand (TRAIL) regulates midline-1, thymic stromal lymphopoietin, inflammation, and remodeling in experimental eosinophilic esophagitis. J Allergy Clin Immunol. 2015;136:971–982.
   PubMed Web of Science ®Google Scholar
• Cultrone A, de Wouters T, Lakhdari O, et al. The NF-kappaB binding site located in the proximal region of the TSLP promoter is critical for TSLP modulation in human intestinal epithelial cells. Eur J Immunol. 2013;43:1053–1062.
   PubMed Web of Science ®Google Scholar
• Fornasa G, Tsilingiri K, Caprioli F, et al. Dichotomy of short and long thymic stromal lymphopoietin isoforms in inflammatory disorders of the bowel and skin. J Allergy Clin Immunol. 2015;136:413–422.
   PubMed Web of Science ®Google Scholar
• Harada M, Hirota T, Jodo AI, et al. Functional analysis of the thymic stromal lymphopoietin variants in human bronchial epithelial cells. Am J Respir Cell Mol Biol. 2009;40:368–374.
   PubMed Web of Science ®Google Scholar
• Iliev ID, Spadoni I, Mileti E, et al. Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. Gut. 2009;58:1481–1489.
   PubMed Web of Science ®Google Scholar
• Kato A, Favoreto S Jr., Avila PC, et al. TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells. J Immunol. 2007;179:1080–1087.
   PubMed Web of Science ®Google Scholar
• Lee HC, Headley MB, Loo YM, et al. Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection. J Allergy Clin Immunol. 2012;130:1187–1196 e5.
   PubMed Web of Science ®Google Scholar
• Lee HC, Ziegler SF. Inducible expression of the proallergic cytokine thymic stromal lymphopoietin in airway epithelial cells is controlled by NFkappaB. Proc Natl Acad Sci U S A. 2007;104:914–919.
   PubMed Web of Science ®Google Scholar
• Nagarkar DR, Poposki JA, Comeau MR, et al. Airway epithelial cells activate TH2 cytokine production in mast cells through IL-1 and thymic stromal lymphopoietin. J Allergy Clin Immunol. 2012;130:225–32 e4.
   PubMed Web of Science ®Google Scholar
• Bjerkan L, Schreurs O, Engen SA, et al. The short form of TSLP is constitutively translated in human keratinocytes and has characteristics of an antimicrobial peptide. Mucosal Immunol. 2015;8:49–56.
   PubMed Web of Science ®Google Scholar
• Vu AT, Baba T, Chen X, et al. Staphylococcus aureus membrane and diacylated lipopeptide induce thymic stromal lymphopoietin in keratinocytes through the Toll-like receptor 2-Toll-like receptor 6 pathway. J Allergy Clin Immunol. 2010;126:985–93, 993 e1-3.
   PubMed Web of Science ®Google Scholar
• Li M, Hener P, Zhang Z, et al. Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc Natl Acad Sci U S A. 2006;103:11736–11741.
   PubMed Web of Science ®Google Scholar
• Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3:673–680.
   PubMed Web of Science ®Google Scholar
• Kashyap M, Rochman Y, Spolski R, et al. Thymic stromal lymphopoietin is produced by dendritic cells. J Immunol. 2011;187:1207–1211.
   PubMed Web of Science ®Google Scholar
• Zhang K, Shan L, Rahman MS, et al. Constitutive and inducible thymic stromal lymphopoietin expression in human airway smooth muscle cells: role in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2007;293:L375–L382.
   PubMed Web of Science ®Google Scholar
• Allakhverdi Z, Comeau MR, Jessup HK, et al. Thymic stromal lymphopoietin as a mediator of crosstalk between bronchial smooth muscles and mast cells. J Allergy Clin Immunol. 2009;123:958–60 e2.
   PubMed Web of Science ®Google Scholar
• Okayama Y, Okumura S, Sagara H, et al. FcepsilonRI-mediated thymic stromal lymphopoietin production by interleukin-4-primed human mast cells. Eur Respir J. 2009;34:425–435.
   PubMed Web of Science ®Google Scholar
• Allakhverdi Z, Comeau MR, Jessup HK, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med. 2007;204:253–258.
   PubMed Web of Science ®Google Scholar
• Ying S, O’Connor B, Ratoff J, et al. Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease. J Immunol. 2008;181:2790–2798.
   PubMed Web of Science ®Google Scholar
• Sokol CL, Barton GM, Farr AG, et al. A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat Immunol. 2008;9:310–318.
   PubMed Web of Science ®Google Scholar
• Watanabe N, Wang YH, Lee HK, et al. Hassall’s corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature. 2005;436:1181–1185.
   PubMed Web of Science ®Google Scholar
• Hanabuchi S, Ito T, Park WR, et al. Thymic stromal lymphopoietin-activated plasmacytoid dendritic cells induce the generation of FOXP3+ regulatory T cells in human thymus. J Immunol. 2010;184:2999–3007.
   PubMed Web of Science ®Google Scholar
• Pattarini L, Trichot C, Bogiatzi S, et al. TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand. J Exp Med. 2017;214:1529–1546.
   PubMed Web of Science ®Google Scholar
• Kuroda Y, Yuki T, Takahashi Y, et al. Long form of thymic stromal lymphopoietin of keratinocytes is induced by protein allergens. J Immunotoxicol. 2017;14:178–187.
   PubMed Web of Science ®Google Scholar
• Xie Y, Takai T, Chen X, et al. Long TSLP transcript expression and release of TSLP induced by TLR ligands and cytokines in human keratinocytes. J Dermatol Sci. 2012;66:233–237.
   PubMed Web of Science ®Google Scholar
• Kouzaki H, O’Grady SM, Lawrence CB, et al. Proteases induce production of thymic stromal lymphopoietin by airway epithelial cells through protease-activated receptor-2. J Immunol. 2009;183:1427–1434.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Miyata M, Ohba T, et al. Cigarette smoke extract induces thymic stromal lymphopoietin expression, leading to T(H)2-type immune responses and airway inflammation. J Allergy Clin Immunol. 2008;122:1208–1214.
   PubMed Web of Science ®Google Scholar
• Smelter DF, Sathish V, Thompson MA, et al. Thymic stromal lymphopoietin in cigarette smoke-exposed human airway smooth muscle. J Immunol. 2010;185:3035–3040.
   PubMed Web of Science ®Google Scholar
• Wilson SR, The L, Batia LM, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell. 2013;155:285–295.
   PubMed Web of Science ®Google Scholar
• Borowski A, Vetter T, Kuepper M, et al. Expression analysis and specific blockade of the receptor for human thymic stromal lymphopoietin (TSLP) by novel antibodies to the human TSLPRalpha receptor chain. Cytokine. 2013;61:546–555.
   PubMed Web of Science ®Google Scholar
• Zhang F, Huang G, Hu B, et al. A soluble thymic stromal lymphopoietin (TSLP) antagonist, TSLPR-immunoglobulin, reduces the severity of allergic disease by regulating pulmonary dendritic cells. Clin Exp Immunol. 2011;164:256–264.
   PubMed Web of Science ®Google Scholar
• Ye L, Mou Y, Wang J, et al. Effects of microRNA-19b on airway remodeling, airway inflammation and degree of oxidative stress by targeting TSLP through the Stat3 signaling pathway in a mouse model of asthma. Oncotarget. 2017;8:47533–47546.
   PubMedGoogle Scholar
• Omori M, Ziegler S. Induction of IL-4 expression in CD4(+) T cells by thymic stromal lymphopoietin. J Immunol. 2007;178:1396–1404.
   PubMed Web of Science ®Google Scholar
• Angkasekwinai P, Park H, Wang YH, et al. Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med. 2007;204:1509–1517.
   PubMed Web of Science ®Google Scholar
• Drake LY, Kita H. IL-33: biological properties, functions, and roles in airway disease. Immunol Rev. 2017;278:173–184.
   PubMed Web of Science ®Google Scholar
• Stier MT, Zhang J, Goleniewska K, et al. IL-33 promotes the egress of group 2 innate lymphoid cells from the bone marrow. J Exp Med. 2018;215:263–281.
   PubMed Web of Science ®Google Scholar
• Halim TY, Krauss RH, Sun AC, et al. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity. 2012;36:451–463.
   PubMed Web of Science ®Google Scholar
• Martin NT, Martin MU. Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol. 2016;17:122–131.
   PubMed Web of Science ®Google Scholar
• Kabata H, Moro K, Fukunaga K, et al. Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation. Nat Commun. 2013;4:2675.
   PubMed Web of Science ®Google Scholar
• He R, Oyoshi MK, Garibyan L, et al. TSLP acts on infiltrating effector T cells to drive allergic skin inflammation. Proc Natl Acad Sci U S A. 2008;105:11875–11880.
   PubMed Web of Science ®Google Scholar
• Ochiai S, Jagot F, Kyle RL, et al. Thymic stromal lymphopoietin drives the development of IL-13(+) Th2 cells. Proc Natl Acad Sci U S A. 2018;115:1033–1038.
   PubMed Web of Science ®Google Scholar
• Milford TA, Su RJ, Francis OL, et al. TSLP or IL-7 provide an IL-7Ralpha signal that is critical for human B lymphopoiesis. Eur J Immunol. 2016;46:2155–2161.
   PubMed Web of Science ®Google Scholar
• Borriello F, Iannone R, Di Somma S, et al. Lipopolysaccharide-elicited TSLPR expression enriches a functionally discrete subset of human CD14(+) CD1c(+) monocytes. J Immunol. 2017;198:3426–3435.
   PubMed Web of Science ®Google Scholar
• Wong CK, Hu S, Cheung PF, et al. Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation. Am J Respir Cell Mol Biol. 2010;43:305–315.
   PubMed Web of Science ®Google Scholar
• Morshed M, Yousefi S, Stockle C, et al. Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps. Allergy. 2012;67:1127–1137.
   PubMed Web of Science ®Google Scholar
• Cook EB, Stahl JL, Schwantes EA, et al. IL-3 and TNFalpha increase Thymic Stromal Lymphopoietin Receptor (TSLPR) expression on eosinophils and enhance TSLP-stimulated degranulation. Clin Mol Allergy. 2012;10:8.
   PubMedGoogle Scholar
• Noh JY, Shin JU, Park CO, et al. Thymic stromal lymphopoietin regulates eosinophil migration via phosphorylation of l-plastin in atopic dermatitis. Exp Dermatol. 2016;25:880–886.
   PubMed Web of Science ®Google Scholar
• Siracusa MC, Saenz SA, Hill DA, et al. TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. Nature. 2011;477:229–233.
   PubMed Web of Science ®Google Scholar
• Salter BM, Oliveria JP, Nusca G, et al. Thymic stromal lymphopoietin activation of basophils in patients with allergic asthma is IL-3 dependent. J Allergy Clin Immunol. 2015;136:1636–1644.
   PubMed Web of Science ®Google Scholar
• Salabert-Le Guen N, Hemont C, Delbove A, et al. Thymic stromal lymphopoietin does not activate human basophils. J Allergy Clin Immunol. 2018;141:1476–1479 e6.
   PubMed Web of Science ®Google Scholar
• Han NR, Oh HA, Nam SY, et al. TSLP induces mast cell development and aggravates allergic reactions through the activation of MDM2 and STAT6. J Invest Dermatol. 2014;134:2521–2530.
   PubMed Web of Science ®Google Scholar
• Kaur D, Doe C, Woodman L, et al. Mast cell-airway smooth muscle crosstalk: the role of thymic stromal lymphopoietin. Chest. 2012;142:76–85.
   PubMed Web of Science ®Google Scholar
• Buchheit KM, Cahill KN, Katz HR, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137:1566–1576 e5.
   PubMed Web of Science ®Google Scholar
• Harada M, Hirota T, Jodo AI, et al. Thymic stromal lymphopoietin gene promoter polymorphisms are associated with susceptibility to bronchial asthma. Am J Respir Cell Mol Biol. 2011;44:787–793.
   PubMed Web of Science ®Google Scholar
• Dong H, Hu Y, Liu L, et al. Distinct roles of short and long thymic stromal lymphopoietin isoforms in house dust mite-induced asthmatic airway epithelial barrier disruption. Sci Rep. 2016;6:39559.
   PubMed Web of Science ®Google Scholar
• Nagarkar DR, Poposki JA, Tan BK, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;132:593–600 e12.
   PubMed Web of Science ®Google Scholar
• Poposki JA, Klingler AI, Stevens WW, et al. Proprotein convertases generate a highly functional heterodimeric form of thymic stromal lymphopoietin in humans. J Allergy Clin Immunol. 2017;139:1559–1567 e8.
   PubMed Web of Science ®Google Scholar
• Gudbjartsson DF, Bjornsdottir US, Halapi E, et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet. 2009;41:342–347.
   PubMed Web of Science ®Google Scholar
• He JQ, Hallstrand TS, Knight D, et al. A thymic stromal lymphopoietin gene variant is associated with asthma and airway hyperresponsiveness. J Allergy Clin Immunol. 2009;124:222–229.
   PubMed Web of Science ®Google Scholar
• Liu W, Xu LS, Liu QJ, et al. Two single nucleotide polymorphisms in TSLP gene are associated with asthma susceptibility in Chinese Han population. Exp Lung Res. 2012;38:375–382.
   PubMed Web of Science ®Google Scholar
• Al-Shami A, Spolski R, Kelly J, et al. A role for TSLP in the development of inflammation in an asthma model. J Exp Med. 2005;202:829–839.
   PubMed Web of Science ®Google Scholar
• Zhou B, Comeau MR, De Smedt T, et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol. 2005;6:1047–1053.
   PubMed Web of Science ®Google Scholar
• Headley MB, Zhou B, Shih WX, et al. TSLP conditions the lung immune environment for the generation of pathogenic innate and antigen-specific adaptive immune responses. J Immunol. 2009;182:1641–1647.
   PubMed Web of Science ®Google Scholar
• Hu Y, Dong H, Zou M, et al. TSLP signaling blocking alleviates E-cadherin dysfunction of airway epithelium in a HDM-induced asthma model. Cell Immunol. 2017;315:56–63.
   PubMed Web of Science ®Google Scholar
• Shikotra A, Choy DF, Ohri CM, et al. Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma. J Allergy Clin Immunol. 2012;129:104–11 e1-9.
   PubMed Web of Science ®Google Scholar
• Ying S, O’Connor B, Ratoff J, et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol. 2005;174:8183–8190.
   PubMed Web of Science ®Google Scholar
• Berraies A, Hamdi B, Ammar J, et al. Increased expression of thymic stromal lymphopoietin in induced sputum from asthmatic children. Immunol Lett. 2016;178:85–91.
   PubMed Web of Science ®Google Scholar
• Gluck J, Rymarczyk B, Kasprzak M, et al. Increased Levels of Interleukin-33 and thymic stromal lymphopoietin in exhaled breath condensate in chronic bronchial asthma. Int Arch Allergy Immunol. 2016;169:51–56.
   PubMed Web of Science ®Google Scholar
• Chauhan A, Singh M, Agarwal A, et al. Correlation of TSLP, IL-33, and CD4 + CD25 + FOXP3 + T regulatory (Treg) in pediatric asthma. J Asthma. 2015;52:868–872.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang W, Lv Z, et al. Elevated expression of IL-33 and TSLP in the airways of human asthmatics in vivo: a potential biomarker of severe refractory disease. J Immunol. 2018;200:2253–2262.
   PubMed Web of Science ®Google Scholar
• Wang W, Li Y, Lv Z, et al. Bronchial allergen challenge of patients with atopic asthma triggers an alarmin (IL-33, TSLP, and IL-25) response in the airways epithelium and submucosa. J Immunol. 2018;201:2221–2231.
   PubMed Web of Science ®Google Scholar
• Al-Sajee D, Sehmi R, Hawke TJ, et al. Expression of IL-33 and TSLP and their receptors in asthmatic airways after inhaled allergen challenge. Am J Respir Crit Care Med. 2018;198:805–807.
   PubMed Web of Science ®Google Scholar
• Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137:1449–1456 e4.
   PubMed Web of Science ®Google Scholar
• Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Annu Rev Pathol. 2017;12:331–357.
   PubMed Web of Science ®Google Scholar
• Bresciani M, Paradis L, Des Roches A, et al. Rhinosinusitis in severe asthma. J Allergy Clin Immunol. 2001;107:73–80.
   PubMed Web of Science ®Google Scholar
• Sun Q, Liu Y, Zhang S, et al. Thymic stromal lymphopoietin polymorphisms and allergic rhinitis risk: a systematic review and meta-analysis with 6351 cases and 11472 controls. Int J Clin Exp Med. 2015;8:15752–15758.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370:2102–2110.
   PubMed Web of Science ®Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017;377:936–946.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455–2466.
   PubMed Web of Science ®Google Scholar
• Malinovschi A, Janson C, Borres M, et al. Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity. J Allergy Clin Immunol. 2016;138:1301–1308 e2.
   PubMed Web of Science ®Google Scholar
• Busse WW. A role for neutrophils in asthma exacerbations. Nat Med. 2017;23:658–659.
   PubMed Web of Science ®Google Scholar
• Venkataramani S, Low S, Weigle B, et al. Design and characterization of zweimab and doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies. Biochem Biophys Res Commun. 2018;504:19–24.
   PubMed Web of Science ®Google Scholar
• Datta A, Alexander R, Sulikowski MG, et al. Evidence for a functional thymic stromal lymphopoietin signaling axis in fibrotic lung disease. J Immunol. 2013;191:4867–4879.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:659–668.
   PubMed Web of Science ®Google Scholar
• Staiano RI, Loffredo S, Borriello F, et al. Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. J Leukoc Biol. 2016;99:531–540.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Galdiero MR, Loffredo S, et al. Are mast cells MASTers in cancer? Front Immunol. 2017;8:424.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Galdiero MR, Marone G, et al. Controversial role of mast cells in skin cancers. Exp Dermatol. 2017;26:11–17.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Loffredo S, Galdiero MR, et al. Innate effector cells in angiogenesis and lymphangiogenesis. Curr Opin Immunol. 2018;53:152–160.
   PubMed Web of Science ®Google Scholar
• Lo Kuan E, Ziegler SF. Thymic stromal lymphopoietin and cancer. J Immunol. 2014;193:4283–4288.
   PubMed Web of Science ®Google Scholar
• De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011;208:469–478.
   PubMed Web of Science ®Google Scholar
• Olkhanud PB, Rochman Y, Bodogai M, et al. Thymic stromal lymphopoietin is a key mediator of breast cancer progression. J Immunol. 2011;186:5656–5662.
   PubMed Web of Science ®Google Scholar
• Ferretti E, Hohaus S, Di Napoli A, et al. Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from hodgkin lymphoma patients. Oncotarget. 2017;8:85263–85275.
   PubMedGoogle Scholar
• Kuan EL, Ziegler SF. A tumor-myeloid cell axis, mediated via the cytokines IL-1alpha and TSLP, promotes the progression of breast cancer. Nat Immunol. 2018;19:366–374.
   PubMed Web of Science ®Google Scholar
• Demehri S, Turkoz A, Manivasagam S, et al. Elevated epidermal thymic stromal lymphopoietin levels establish an antitumor environment in the skin. Cancer Cell. 2012;22:494–505.
   PubMed Web of Science ®Google Scholar
• Demehri S, Cunningham TJ, Manivasagam S, et al. Thymic stromal lymphopoietin blocks early stages of breast carcinogenesis. J Clin Invest. 2016;126:1458–1470.
   PubMed Web of Science ®Google Scholar
• Yue W, Lin Y, Yang X, et al. Thymic stromal lymphopoietin (TSLP) inhibits human colon tumor growth by promoting apoptosis of tumor cells. Oncotarget. 2016;7:16840–16854.
   PubMedGoogle Scholar
• Di Piazza M, Nowell CS, Koch U, et al. Loss of cutaneous TSLP-dependent immune responses skews the balance of inflammation from tumor protective to tumor promoting. Cancer Cell. 2012;22:479–493.
   PubMed Web of Science ®Google Scholar
• Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46:1308–1321.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Pedersen S, Lamm CJ, et al. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med. 2009;179:19–24.
   PubMed Web of Science ®Google Scholar
• Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68:1119–1124.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–1197.
   PubMed Web of Science ®Google Scholar
• Saglani S, Lloyd CM. Eosinophils in the pathogenesis of paediatric severe asthma. Curr Opin Allergy Clin Immunol. 2014;14:143–148.
   PubMed Web of Science ®Google Scholar
• Anderson WC 3rd, Szefler SJ. New and future strategies to improve asthma control in children. J Allergy Clin Immunol. 2015;136:848–859.
   PubMed Web of Science ®Google Scholar